NASDAQ:INCY Incyte - INCY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. $85.70 -0.31 (-0.36%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$85.42▼$86.0850-Day Range$77.45▼$86.0152-Week Range$65.07▼$86.29Volume931,526 shsAverage Volume1.88 million shsMarket Capitalization$19.07 billionP/E Ratio21.81Dividend YieldN/APrice Target$78.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Incyte MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside8.1% Downside$78.75 Price TargetShort InterestHealthy1.99% of Shares Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.49Based on 10 Articles This WeekInsider TradingSelling Shares$3.77 M Sold Last QuarterProj. Earnings Growth56.07%From $2.14 to $3.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector186th out of 1,055 stocksCommercial Physical Research Industry4th out of 17 stocks 1.0 Analyst's Opinion Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 5 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $78.75, Incyte has a forecasted downside of 8.1% from its current price of $85.71.Amount of Analyst CoverageIncyte has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.99% of the outstanding shares of Incyte have been sold short.Short Interest Ratio / Days to CoverIncyte has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Incyte has recently decreased by 10.34%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIncyte does not currently pay a dividend.Dividend GrowthIncyte does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIncyte has received a 71.02% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cancer medication (L01)", "Pharmacovigilance services", and "Clinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Incyte is -1.23. Previous Next 2.5 News and Social Media Coverage News SentimentIncyte has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Incyte this week, compared to 6 articles on an average week.Search Interest4 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,765,933.00 in company stock.Percentage Held by Insiders17.50% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.08% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Incyte are expected to grow by 56.07% in the coming year, from $2.14 to $3.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Incyte is 21.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Incyte is 21.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 113.54.Price to Earnings Growth RatioIncyte has a PEG Ratio of 1.14. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIncyte has a P/B Ratio of 5.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Incyte (NASDAQ:INCY) StockIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.Read More Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Stock News HeadlinesJanuary 24, 2023 | seekingalpha.comIncyte: Opzelura Is The Main Growth DriverJanuary 23, 2023 | americanbankingnews.comIncyte Co. (NASDAQ:INCY) Sees Large Decline in Short InterestJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 22, 2023 | seekingalpha.comIncyte: Making Hay While The Sun ShinesJanuary 22, 2023 | americanbankingnews.comIncyte Co. (NASDAQ:INCY) Receives $78.86 Average Price Target from BrokeragesJanuary 20, 2023 | finance.yahoo.comIncyte Gets a Quantitative UpgradeJanuary 5, 2023 | marketwatch.comTyrosine Kinase JAK Inhibitors Market 2023 : Profiling Key Players, Value Estimation and Analysis by Recent Trends to 2028December 26, 2022 | finance.yahoo.comThe 7 Hottest Healthcare Stocks to Own for 2023 and BeyondJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 11, 2022 | finance.yahoo.comIncyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific SessionDecember 2, 2022 | finance.yahoo.comIncyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast AsiaNovember 7, 2022 | finance.yahoo.comData From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingNovember 7, 2022 | finance.yahoo.comIncyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid TumorsNovember 2, 2022 | seekingalpha.comIncyte A Buy As Revenue From Opzelura RampsOctober 25, 2022 | finance.yahoo.comEarnings Preview: Incyte (INCY) Q3 Earnings Expected to DeclineOctober 20, 2022 | finance.yahoo.comRecludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology - Yahoo FinanceOctober 19, 2022 | businesswire.comPivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine - Business WireOctober 19, 2022 | finance.yahoo.comTheseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors - Yahoo FinanceOctober 18, 2022 | benzinga.comExpert Ratings for Incyte - Incyte (NASDAQ:INCY) - BenzingaOctober 18, 2022 | finance.yahoo.comAnalyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm' - Yahoo FinanceOctober 17, 2022 | bizjournals.comMacroGenics strikes deal with Gilead Sciences - Washington Business Journal - The Business JournalsOctober 17, 2022 | nasdaq.comHere's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now - NasdaqOctober 17, 2022 | nasdaq.comIs Incyte (INCY) a Solid Growth Stock? 3 Reasons to Think "Yes" - NasdaqOctober 16, 2022 | finance.yahoo.comInnovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine - Yahoo FinanceOctober 15, 2022 | nasdaq.comFriday Sector Leaders: Healthcare, Consumer Products - NasdaqOctober 13, 2022 | thestreet.comIs Incyte Building a Vitiligo Empire? - TheStreetOctober 11, 2022 | finance.yahoo.comEsophageal Cancer Clinical Trial Pipeline Insights Featuring 80+ Companies | DelveInsight - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter. Email Address INCY Company Calendar Last Earnings11/01/2022Today1/27/2023Next Earnings (Confirmed)2/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INCY CUSIP45337C10 CIK879169 Webwww.incyte.com Phone(302) 498-6700Fax302-425-2750Employees2,094Year Founded1991Price Target and Rating Average Stock Price Forecast$78.75 High Stock Price Forecast$98.00 Low Stock Price Forecast$63.00 Forecasted Upside/Downside-8.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$3.93 Trailing P/E Ratio21.81 Forward P/E Ratio40.05 P/E Growth1.14Net Income$948.58 million Net Margins26.30% Pretax Margin17.07% Return on Equity9.04% Return on Assets6.92% Debt Debt-to-Equity Ratio0.01 Current Ratio3.80 Quick Ratio3.75 Sales & Book Value Annual Sales$2.99 billion Price / Sales6.38 Cash Flow$2.40 per share Price / Cash Flow35.73 Book Value$17.07 per share Price / Book5.02Miscellaneous Outstanding Shares222,475,000Free Float183,542,000Market Cap$19.07 billion OptionableOptionable Beta0.70 Social Links Key ExecutivesHerve HoppenotChairman, President & Chief Executive OfficerChristiana StamoulisChief Financial Officer & Executive Vice PresidentSteven H. SteinChief Medical Officer & Executive Vice PresidentDashyant DhanakChief Scientific Officer & Executive VPBarry FlannellyEVP & General Manager-North AmericaKey CompetitorsICON PublicNASDAQ:ICLRCharles River Laboratories InternationalNYSE:CRLMedpaceNASDAQ:MEDPWest Pharmaceutical ServicesNYSE:WSTAlign TechnologyNASDAQ:ALGNView All CompetitorsInsiders & InstitutionsState of Michigan Retirement SystemBought 200 shares on 1/27/2023Ownership: 0.023%Strs OhioBought 475 shares on 1/26/2023Ownership: 0.012%Sumitomo Mitsui DS Asset Management Company LtdSold 152 shares on 1/26/2023Ownership: 0.009%Girard Partners LTD.Bought 257 shares on 1/26/2023Ownership: 0.007%Tokio Marine Asset Management Co. Ltd.Bought 307 shares on 1/26/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions INCY Stock - Frequently Asked Questions Should I buy or sell Incyte stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares. View INCY analyst ratings or view top-rated stocks. What is Incyte's stock price forecast for 2023? 7 brokerages have issued 1-year price targets for Incyte's shares. Their INCY share price forecasts range from $63.00 to $98.00. On average, they expect the company's stock price to reach $78.75 in the next twelve months. This suggests that the stock has a possible downside of 8.4%. View analysts price targets for INCY or view top-rated stocks among Wall Street analysts. How have INCY shares performed in 2023? Incyte's stock was trading at $80.32 at the beginning of 2023. Since then, INCY shares have increased by 7.1% and is now trading at $86.01. View the best growth stocks for 2023 here. When is Incyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023. View our INCY earnings forecast. How can I listen to Incyte's earnings call? Incyte will be holding an earnings conference call on Tuesday, February 7th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13735569". How were Incyte's earnings last quarter? Incyte Co. (NASDAQ:INCY) posted its earnings results on Tuesday, November, 1st. The biopharmaceutical company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.54 by $0.10. The biopharmaceutical company earned $823.30 million during the quarter, compared to analysts' expectations of $847 million. Incyte had a trailing twelve-month return on equity of 9.04% and a net margin of 26.30%. What is Hervé Hoppenot's approval rating as Incyte's CEO? 22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees. What other stocks do shareholders of Incyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA). What is Incyte's stock symbol? Incyte trades on the NASDAQ under the ticker symbol "INCY." Who are Incyte's major shareholders? Incyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.50%), ARK Investment Management LLC (0.43%), Country Trust Bank (0.21%), Allspring Global Investments Holdings LLC (0.20%), Grimes & Company Inc. (0.09%) and National Bank of Canada FI (0.05%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View institutional ownership trends. How do I buy shares of Incyte? Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Incyte's stock price today? One share of INCY stock can currently be purchased for approximately $86.01. How much money does Incyte make? Incyte (NASDAQ:INCY) has a market capitalization of $19.14 billion and generates $2.99 billion in revenue each year. The biopharmaceutical company earns $948.58 million in net income (profit) each year or $3.93 on an earnings per share basis. How many employees does Incyte have? The company employs 2,094 workers across the globe. How can I contact Incyte? Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750. This page (NASDAQ:INCY) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.